In the past week, SLS stock has gone down by -16.40%, with a monthly decline of -2.47% and a quarterly surge of 36.21%. The volatility ratio for the week is 3.83%, and the volatility levels for the last 30 days are 6.34% for SELLAS Life Sciences Group Inc The simple moving average for the last 20 days is -6.56% for SLS’s stock, with a simple moving average of 26.78% for the last 200 days.
Is It Worth Investing in SELLAS Life Sciences Group Inc (NASDAQ: SLS) Right Now?
The 36-month beta value for SLS is at 2.26. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLS is 97.68M, and currently, shorts hold a 8.96% of that float. The average trading volume for SLS on June 03, 2025 was 1.80M shares.
SLS) stock’s latest price update
The stock of SELLAS Life Sciences Group Inc (NASDAQ: SLS) has decreased by -7.60 when compared to last closing price of 1.71.Despite this, the company has seen a loss of -16.40% in its stock price over the last five trading days. globenewswire.com reported 2025-06-02 that – ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – – 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical efficacy of SLS009 (tambiciclib) in ASXL1 mutated colorectal cancer lines. The data are featured in a presentation, entitled “In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines” at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30- June 3, 2025, in Chicago, Illinois.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight.” The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
H.C. Wainwright gave a rating of “Buy” to SLS, setting the target price at $11 in the report published on April 02nd of the previous year.
SLS Trading at 11.02% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.47% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLS starting from Wasman Jane, who purchase 20,000 shares at the price of $1.69 back on May 30 ’25. After this action, Wasman Jane now owns 30,400 shares of SELLAS Life Sciences Group Inc, valued at $33,800 using the latest closing price.
Kalin Katherine Bach, the Director of SELLAS Life Sciences Group Inc, purchase 20,000 shares at $1.80 during a trade that took place back on May 22 ’25, which means that Kalin Katherine Bach is holding 41,000 shares at $36,000 based on the most recent closing price.
Stock Fundamentals for SLS
The total capital return value is set at -1.0. Equity return is now at value -144.90, with -91.36 for asset returns.
Based on SELLAS Life Sciences Group Inc (SLS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -38.75.
Currently, EBITDA for the company is -30.88 million with net debt to EBITDA at 0.99. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.64.
Conclusion
In conclusion, SELLAS Life Sciences Group Inc (SLS) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
